普洛藥業(000739.SZ):擬使用不超15億元自有閒置資金進行理財投資
格隆匯3月9日丨普洛藥業(000739.SZ)公佈,為進一步提高公司及下屬公司的資金使用效益,降低公司的資金成本,在保證公司正常生產經營的資金需求及資金安全的前提下,擬使用不超過15億元自有閒置資金的額度進行理財產品的投資,該額度內由公司及下屬控股子公司和孫公司共同滾動使用,使用期限自公司2021年年股東大會審議通過之日起至2022年年度股東大會召開之日止。同時,提請股東大會授權公司董事長行使該項投資決策權並簽署相關合同文件,並由公司相關部門負責具體實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.